Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 12/20 | 0.38 |
| ▸ | BCR | P11274 | 12/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | BPTF | Q12830 | 2/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.34 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.34 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.34 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.34 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.34 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.34 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4665810 | 0.96 | ABL1 (0.39) | ABL1BCRTP53HTR6TNNI3K | |
| SCHEMBL4666209 | 0.95 | ABL1 (0.38) | ABL1BCRTP53BPTFTNNI3K | |
| SCHEMBL4666098 | 0.94 | BPTF (0.35) | ABL1BCRTP53BPTFHTR6 | |
| SCHEMBL4665744 | 0.93 | MEN1 (0.38) | ABL1BCRTP53BPTFHTR6 | |
| SCHEMBL4667474 | 0.90 | BACE1 (0.35) | ABL1BCRTP53BPTFHTR6 | |
| SCHEMBL4666150 | 0.90 | BPTF (0.35) | ABL1BCRTP53BPTFHTR6 | |
| SCHEMBL4665626 | 0.89 | BPTF (0.39) | ABL1BCRBPTFHTR6 | |
| SCHEMBL4667523 | 0.88 | HTR6 (0.38) | ABL1BCRBPTFHTR6TNNI3K | |
| SCHEMBL4666086 | 0.88 | HRH3 (0.44) | ABL1BCRHRH3PSEN1PSEN2 | |
| SCHEMBL4666028 | 0.88 | ABL1 (0.38) | ABL1BCRTNNI3K |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242681-A1 | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors | ALTANA PHARMA AG (DE) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242681-A1 | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors | MAP3K19, MAP3K6, MAP3K20 | ABL1 24/4885BCR 402/4885TP53 2301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.